Azvudine · FNC
Small molecule
Evidence outlook
Approved: COVID-19 in adult patients (conditional approval) (CN)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Partial signal
Also in development:COVID-19 · Phase 3 · investigational in the US
Also approved (2)
- COVID-19 in adult patients (conditional approval)
- HIV-1 infection, high viral load, combination therapy (conditional)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04303598 NCT04303598 · HIV-infection/Aids This is a randomized, double-blind, active-controlled trial testing whether azvudine achieves viral suppression as well as an established comparator, using a recognized clinical measure of HIV control, but results are not yet posted so the outcome is unknown. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.) Registry: NCT04303598 | 3 | Rate of subjects with plasma HIV-1 Ribonucleic acid (RNA) <50 copies/milliliter (c/mL) at Week 48 (48 Weeks) 2022-05-01 | Results not posted; external-source review pending | Partial signal | link ↗ |
View 1 more trial
NCT04109183 NCT04109183 · AIDS The study used randomized, triple-blind, active-controlled groups with 172 participants, and its primary endpoint was the clinically meaningful HIV-1 RNA suppression measure. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT04109183 | 2 | Evaluation of azivudine tablet (FNC) combined with reverse transcriptase inhibitor therapy without anti-hiv treatment. (At 48 weeks); Preliminary evaluation of the efficacy of azivudine tablets (FNC) combined with reverse transcriptase inhibitors in the treatment of patients who have not received anti-hiv treatment. (At 48 weeks) 2019-01-28 | 符合方案集(PPS)阿兹夫定 2 mg 组、阿兹夫定 3 mg 组、阿兹夫定 4 mg 组和 3TC 组结果分别为 97.2%、100%、100% 和 97.5%。经卡方分析各组之间无显著统计学差异(P>0.05) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Competitive landscape
Other HIV reverse transcriptase drugs
Cabotegravir/rilpivirine (Cabenuva), Doravirine, Doravirine/islatravir (Idvynso), Emtricitabine (Emtriva), Emtricitabine/tenofovir disoproxil fumarate and 8 more. Compare all 14 HIV reverse transcriptase drugs
This mechanism is crowded: 13 other tracked programmes target it, 8 of them ahead of this one.
This drug's own stage for COVID-19: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Azvudine (FNC): this drug | Phase 3 | Small molecule | HIV reverse transcriptase | not yet graded | No reviewed efficacy summary in this indication | |
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1806 (Tofidence) | Approved | Monoclonal antibody | IL-6 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| CT-P47 (tocilizumab) (Avtozma) | Approved | Monoclonal antibody | IL-6R antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Elasomeran (Spikevax) | Approved | Vaccine | SARS-CoV-2 spike protein | Reliable signal | No reviewed efficacy summary in this indication | |
| Tocilizumab (Actemra / RoActemra) | Approved | Monoclonal antibody | IL-6 receptor | Partial signal | NCT04409262: Time to Hospital Discharge or "Ready for Discharge" up to Day 28 (Up to Day 28): Remdesivir + Placebo (RDV+Placebo) - mITT Population 14 days (95% CI 11 to 16) | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population 14 days (95% CI 12 to 15) missed NCT04372186: Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 (Up to Day 28): Tocilizumab 12.04 Percentage of Participants (95% CI 8.52 to 16.86) | Placebo 19.26 Percentage of Participants (95% CI 13.34 to 27.36) | |
| Ibuzatrelvir | Phase 3 | Small molecule | SARS-CoV-2 3CL protease | not yet graded | No reviewed efficacy summary in this indication | |
| Levilimab (Ilsira) | Phase 3 | Monoclonal antibody | IL-6 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Masitinib | Phase 2 | Small molecule | KIT (c-Kit), also PDGFR and Lyn/Fyn kinases | not yet graded | No reviewed efficacy summary in this indication | |
| GSK4396687 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
7 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow FNC (Azvudine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.